OSBPL7-IN-1 is an orally bioactive oxysterol-binding protein-like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes the increase of ABCA1 on the plasma membrane without affecting mRNA expression.

Physicochemical Properties

Molecular Formula	C20H19CL2F3N2O3
Molecular Weight	463.28
Exact Mass	462.072
CAS #	1269826-44-9
PubChem CID	51029555
Appearance	White to off-white solid powder
LogP	5.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	5
Heavy Atom Count	30
Complexity	584
Defined Atom Stereocenter Count	2
SMILES	C1CC[C@H]([C@@H](C1)NC(=O)C2=CC(=C(N=C2)OCC(F)(F)F)C3=CC(=C(C=C3)Cl)Cl)O
InChi Key	GYXGGHPMGUITOT-IAGOWNOFSA-N
InChi Code	InChI=1S/C20H19Cl2F3N2O3/c21-14-6-5-11(8-15(14)22)13-7-12(9-26-19(13)30-10-20(23,24)25)18(29)27-16-3-1-2-4-17(16)28/h5-9,16-17,28H,1-4,10H2,(H,27,29)/t16-,17-/m1/s1
Chemical Name	5-(3,4-dichlorophenyl)-N-[(1R,2R)-2-hydroxycyclohexyl]-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	OSBPL7[1] ABCA1[1]
ln Vitro	In human podocytes cultivated in vitro, OSBPL7-IN-1 (compound G or Cpd G; 1-10 µM) increases the plasma membrane ATP-binding cassette transporter (ABCA1) and dramatically increases ABCA1-dependent cholesterol efflux[1].
ln Vivo	In animal models of proteinuric kidney illness, therapy with OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) normalizes proteinuria and avoids the deterioration of renal function[1].
Animal Protocol	Animal/Disease Models: Female balb/c (Bagg ALBino) mouse induced by Adriamycin (ADR)[1] Doses: 100 mg/kg Route of Administration: Oral gavage; daily; for 28 days Experimental Results: Normalized proteinuria, and Dramatically decreased renal fibrosis and renal functional decline.
References	[1]. Matthew B Wright, et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat Commun. 2021 Aug 2;12(1):4662.

Solubility Data

Solubility (In Vitro)

DMSO: 125 mg/mL (269.82 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (4.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.1585 mL	10.7926 mL	21.5852 mL
	5 mM	0.4317 mL	2.1585 mL	4.3170 mL
	10 mM	0.2159 mL	1.0793 mL	2.1585 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.